Pharmaceutical Company Analysis l Report Store l Pharma Intelligence

Company Analysis: Vertex

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

January 25, 2021

Find out more

Big Pharma Outlook 2026

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

June 29, 2017

Find out more

Company Analysis : AbbVie

$3,000.00

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

July 15, 2020

Find out more

Company Analysis: Pfizer

$3,000.00

PharmaVitae explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

August 28, 2020

Find out more

Company Analysis: Biogen

$3,000.00

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

January 25, 2021

Find out more

Company Analysis: UCB

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

January 25, 2021

Find out more

Company Analysis: BioMarin

$3,000.00

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook over 2019–29.

January 25, 2021

Find out more

Company Analysis: Otsuka

$3,000.00

PharmaVitae explores Otsuka’s prescription pharmaceutical performance and outlook over 2019–29.

January 29, 2020

Find out more

Company Analysis: Gilead

$3,000.00

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

January 25, 2021

Find out more

2016 M&A Analysis

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how

they may influence the market and future deal-making.

September 7, 2016

Find out more

Company Analysis: Merck & Co

$3,000.00

PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

January 25, 2021

Find out more

Company Analysis: Ono Pharmaceutical

$3,000.00

PharmaVitae explores Ono Pharmaceutical’s prescription pharmaceutical performance and outlook over 2019–29.

January 29, 2021

Find out more

Company Analysis: Kyowa Kirin

$3,000.00

PharmaVitae explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019–29.

January 28, 2021

Find out more

2016 M&A Outlook

$3,000.00

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds.

September 28, 2016

Find out more

Japan Pharma Outlook 2027

$3,000.00

PharmaVitae explores and visualizes market dynamics in the Japan Pharma peer set out to 2027* through analysis and in-house sales forecasts for more than 320 products.

July 2, 2018

Find out more

Company analysis

Company Analysis: Vertex

Big Pharma Outlook 2026

Company Analysis : AbbVie

Company Analysis: Pfizer

Company Analysis: Biogen

Company Analysis: UCB

Company Analysis: BioMarin

Company Analysis: Otsuka

Company Analysis: Gilead

2016 M&A Analysis

Company Analysis: Merck & Co

Company Analysis: Ono Pharmaceutical

Company Analysis: Kyowa Kirin

2016 M&A Outlook

Japan Pharma Outlook 2027